- Oxytocin
- Prostaglandins (Dinoprostone, Misoprostol)
- Ergot Alkaloids (Ergometrine, Methyl Ergonovine)
- Tranexamic acid
- Pabal
- Carboprost
- Others
Postpartum hemorrhage treatment market size was valued at USD 802.34 in 2022, growing at a CAGR of 5.3% during the forecast period 2023-2029. The Postpartum Hemorrhage (PPH) is an obstetric hemorrhagic condition that is a prime reason for maternal mortality. In postpartum hemorrhagic condition patient loss about 500mL blood in vaginal delivery or approximately 1000mL blood after cesarean delivery. It is categorized into two types namely, primary postpartum hemorrhage and secondary postpartum hemorrhage. Most commonly used drugs in postpartum hemorrhage are oxytocin and misoprostol. Rise in prevalence of multiple pregnancies, inverted uterus, and other pregnancy complication, increase in risk factors for postpartum hemorrhage such as uterine atony, rise in R&D for the innovation of newer drugs, product pipeline of postpartum hemorrhage drugs, and rise in anemia in pregnant woman are anticipated to fuel the postpartum hemorrhage treatment market. However, adverse effects associated with drugs, stringent regulatory guidelines for newer drug approval, and lack of awareness about drugs in underdeveloped countries may impede the growth of postpartum hemorrhage treatment market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Drivers: The Support from healthcare organizations, Rising pregnancy complications. Restraints: Dearth of trained healthcare providers, High cost of the devices.
The postpartum hemorrhage treatment market key players are: Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Pfizer, Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Ferring B.V. (Switzerland), Cipla Inc. (India)
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary |
2. Global Postpartum Hemorrhage Treatment Market Introduction |
2.1.Global Postpartum Hemorrhage Treatment Market - Taxonomy |
2.2.Global Postpartum Hemorrhage Treatment Market - Definitions |
2.2.1.Drug Type |
2.2.2.Route Administration |
2.2.3.Distribution Channel |
2.2.4.Region |
3. Global Postpartum Hemorrhage Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Postpartum Hemorrhage Treatment Market Analysis, 2018-2022 and Forecast 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Postpartum Hemorrhage Treatment Market By Drug Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. Oxytocin |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Prostaglandins (Dinoprostone, Misoprostol) |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Tranexamic acid |
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Pabal |
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Carboprost |
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Others |
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6. Global Postpartum Hemorrhage Treatment Market By Route Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Postpartum Hemorrhage Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Postpartum Hemorrhage Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Oxytocin |
9.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
9.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
9.1.4.Tranexamic acid |
9.1.5.Pabal |
9.1.6.Carboprost |
9.1.7.Others |
9.2. Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Parenteral |
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Oxytocin |
10.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
10.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
10.1.4.Tranexamic acid |
10.1.5.Pabal |
10.1.6.Carboprost |
10.1.7.Others |
10.2. Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Parenteral |
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Oxytocin |
11.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
11.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
11.1.4.Tranexamic acid |
11.1.5.Pabal |
11.1.6.Carboprost |
11.1.7.Others |
11.2. Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Parenteral |
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Oxytocin |
12.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
12.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
12.1.4.Tranexamic acid |
12.1.5.Pabal |
12.1.6.Carboprost |
12.1.7.Others |
12.2. Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Parenteral |
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Postpartum Hemorrhage Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Oxytocin |
13.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
13.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
13.1.4.Tranexamic acid |
13.1.5.Pabal |
13.1.6.Carboprost |
13.1.7.Others |
13.2. Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Parenteral |
13.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG (Switzerland) |
14.2.2.Fresenius Kabi AG (Germany) |
14.2.3.Pfizer, Inc. (U.S.) |
14.2.4.GlaxoSmithKline Plc (U.K.) |
14.2.5.Ferring B.V. (Switzerland) |
14.2.6.Cipla Inc. (India) |
15. Research Methodology |
16. Appendix and Abbreviations |